

Follow-Up After High-Intensity Care for Substance Use Disorder (FUI)

By working together, we can improve health outcomes for your patients, our members. The Healthcare Effectiveness Data and Information Set (HEDIS[®]) helps us measure many aspects of performance. This tip sheet provides key details of the HEDIS measure for Follow-Up After High-Intensity Care for Substance Use Disorder (FUI).

What is the measure?

The percentage of acute inpatient hospitalizations, residential treatment, or withdrawal management visits for a diagnosis of substance use disorder on or between January 1 and December 1 of the measurement year among members age 13 and older that result in a follow-up visit or service for substance use disorder. Two rates are reported:

1. The percentage of visits or discharges for which the member received follow-up for substance use disorder within the 30 days after the visit or discharge
2. The percentage of visits or discharges for which the member received follow-up for substance use disorder within the seven days after the visit or discharge

Exclusions

- Hospice or use of hospice services anytime during the measurement year
- Death anytime during the measurement year
- Nonacute inpatient stays other than behavioral health

Follow-up Visit

30-day follow-up: A follow-up visit or event with any practitioner for a principal diagnosis of substance use disorder within the 30 days after an episode for substance use disorder.

Seven-day follow-up: A follow-up visit or event with any practitioner for a principal diagnosis of substance use disorder within the seven days after an episode for substance use disorder.

Any of the following visits or events with a principal diagnosis of substance use disorder meet criteria for a follow-up visit.

- An acute or nonacute inpatient admission or residential behavioral health (BH) stay
- An outpatient visit; a BH outpatient visit
- An intensive outpatient encounter or partial hospitalization
- A non-residential substance abuse treatment facility visit
- A community mental health center visit
- A telehealth visit; a telephone visit; an e-visit or virtual check-in
- A substance use disorder service; an opioid treatment service that bills monthly or weekly
- An observation visit

Continued next page

All summaries of the measures contained herein are reproduced with permission from HEDIS *Volume 2: Technical Specifications for Health Plans* by the National Committee for Quality Assurance (NCQA). HEDIS[®] is a registered trademark of the NCQA. Please see the final page of this document for the full copyright citation.

Florida Blue is an Independent Licensee of the Blue Cross and Blue Shield Association.

110040 0323R

HEDIS MEASURE: Follow-Up After High-Intensity Care for Substance Use Disorder (FUI) *(continued)*

Follow-up Visit

- Residential BH treatment
- A pharmacotherapy dispensing event for alcohol use disorder treatment medications; opioid use disorder (OUD); treatment medications or medication treatment event for alcohol and other drugs (AOD); and OUD weekly drug treatment

Note:

- Follow-up visits may not occur on the same date of inpatient or residential treatment discharge or detoxification visit.
- Exclude all withdrawal management events when identifying follow-up care for numerator compliance.

Treatment Medications

Opioid Use Disorder Treatment Medications

| Description | Prescription |
|-----------------|--|
| Antagonist | Naltrexone (oral and injectable) |
| Partial agonist | Buprenorphine (sublingual tablet, injection, implant) ¹ Buprenorphine/naloxone (sublingual tablet, buccal film, sublingual film) |

¹Buprenorphine administered via transdermal patch or buccal film are not included because they are FDA-approved for the treatment of pain, not for opioid use disorder.

Methadone is not included in the medication lists for the measure.

Alcohol Use Disorder Treatment Medications

| Description | Prescription |
|----------------------------------|---|
| Aldehyde dehydrogenase inhibitor | Disulfiram (oral) |
| Antagonist | Naltrexone (oral and injectable) |
| Other | Acamprosate (oral and delayed-release tablet) |

Best Practices

1. Engage parents/guardian/family/support system and/or significant others in the treatment plan. Advise them about the importance of treatment and attending appointments.
2. Care should be coordinated between providers and begin when the SUD diagnosis is made. Encourage communication between the behavioral health providers and PCP.
3. Utilize Lucet, a New Directions company, Behavioral Health Network and Case Management services as needed.
 - Florida Blue member services: Use number on the back of the member ID card.
 - You can receive support for coordination of care for your patients, by calling the Lucet case management and physician assistance number: **866-350-2280**.
 - Your patients can talk to a licensed clinician by calling Lucet’s 24/7 Substance Use Hotline at **877-326-2458**.
 - Patients who prefer to schedule their follow-up appointment and need help finding a provider can call the Lucet member services number: **866-287-9569**. Hours are 8 a.m. – 8 p.m. ET, Monday through Friday.

Content reproduced with permission from HEDIS® MY 2023 Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS measures and specifications are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures or specifications. Limited proprietary coding sets are contained in the specifications for convenience, and users should obtain all necessary licenses from the owners of the code sets. NCQA disclaims all liability for use or accuracy of any coding contained in the specifications. To purchase copies of the publication, including the full measures and specifications, visit ncqa.org/publications